Tesaro, Inc. Announces Clearance of Investigational New Drug Application for TSR-011
Published: Oct 03, 2012
WALTHAM, Mass., Oct. 2, 2012 (GLOBE NEWSWIRE) -- TESARO, Inc. (Nasdaq:TSRO) announced today that the Investigational New Drug (IND) application for TSR-011, an orally available ALK inhibitor (targeted anti-cancer agent) has become effective. The Company plans to dose the first patient in a Phase 1/2 clinical study within the next few months.